Specialists project that commercial availability can commence by 2026, relying on regulatory evaluations and trial outcomes
After ruling out the pharmaceutical issues above, consider whether biological factors are limiting your response
When it comes to people with obesity and without diabetes, the 2025 AACE guidelines recommend semaglutide and tirzepatide as first line over other drug classes for a variety of conditions, including those with prediabetes, type 2 diabetes, osteoarthritis, kidney disease, heart failure, fatty liver, cardiovascular protection, and sleep apnea
The enzyme dipeptidyl peptidase-4 (DPP-4) chews through GLP-1 so quickly that its effects are fleeting
Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides